[Articles] Evaluating the use of the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin to harmonise the readouts between commercial SARS-CoV-2
These findings provide proof-of-concept evidence that for the biologically important SARS-CoV-2 spike protein, levels of anti-RBD, S1, or spike IgG binding antibodies can successfully be compared across a range of well validated commercial assays with different designs and format
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.